Niess Lab / Gastroenterology

Kountouras, J. et al. (2026) ‘Helicobacter pylori and Porphyromonas gingivalis infections as emerging biomarkers associated with Correa’s cascade’, 83(1). Available at: https://doi.org/10.1007/s00018-026-06270-6.

Herner, A. et al. (2026) ‘Beyond Weight Reduction: An Updated Systematic Review and Meta-Analysis of Metabolic Syndrome Components and Metabolic Dysfunction-Associated Steatotic Liver Disease Outcomes After Endoscopic Sleeve Gastroplasty’, Journal of Clinical Medicine, 15(17), p. 6633. Available at: https://doi.org/10.3390/jcm15176633.

Neziraj, Tradite et al. (2026) ‘Anti-CD20 B cell depletion is associated with elevated mucosal-originating circulating regulatory IgA B cells in multiple sclerosis’, Science Translational Medicine, 18(859). Available at: https://doi.org/10.1126/scitranslmed.aee1580.

Balanis, T., Doulberis, M. and Tutuian, R. (2026) ‘EUS-guided transmural treatment of afferent loop syndrome: a systematic review and meta-analysis’, Frontiers in Gastroenterology, 5. Available at: https://doi.org/10.3389/fgstr.2026.1853386.

Peyrin-Biroulet, Laurent et al. (2026) ‘Global Roll-Out and Continued Multi-Site Validation of the Artificial Intelligence Histology Instrument for Qualitative Assessment of Histopathology in Ulcerative Colitis’, United European Gastroenterology Journal, 14. Available at: https://doi.org/10.1002/ueg2.70227.

Chen, Mao, Melhem, Hassan and Niess, Jan Hendrik (2026) ‘Genetic deletion of the inflammatory bowel disease-associated risk gene Rgs14 aggravates experimental colitis’, Journal of Immunology Baltimore Md 1950, 215. Available at: https://doi.org/10.1093/jimmun/vkag135.

Kountouras, J. et al. (2026) ‘Helicobacter pylori and Porphyromonas gingivalis as candidate microbial biomarkers linking periodontal disease, MASLD, and cardiovascular risk’, 54(3), pp. 1641–1643. Available at: https://doi.org/10.1007/s15010-026-02816-9.

Kountouras, J. et al. (2026) ‘Helicobacter pylori and Porphyromonas gingivalis as risk factors for local oral and systemic disorders’, 30(6). Available at: https://doi.org/10.1007/s00784-026-06922-8.

Eleftheriou, M. et al. (2026) ‘Recent evidence on quality of life following total gastrectomy for gastric cancer: A scoping review’, Medicine International, 6(3), pp. 1–22. Available at: https://doi.org/10.3892/mi.2026.314.

Katsiaflaka, A. et al. (2026) ‘Impact of pediatric gastrointestinal disorders on learning and cognitive development in schoolchildren’, 39(2), pp. 174–183. Available at: https://doi.org/10.20524/aog.2026.1044.

Kountouras, J. et al. (2026) ‘Impact of Helicobacter pylori eradication on the progression of Correa’s cascade’, 39(2), pp. 278–280. Available at: https://doi.org/10.20524/aog.2026.1049.

Kountouras, J. et al. (2026) ‘A potential impact of Helicobacter pylori–related metabolic syndrome on the course of high-grade dysplasia in Barrett’s esophagus’, 103(4), pp. 823–824. Available at: https://doi.org/10.1016/j.gie.2025.09.057.

Dylgjeri, Sara et al. (2026) ‘Cytochrome P450 Cyp2s1 regulation of the intestinal metabolome and microbiome’, Mucosal Immunology, 19. Available at: https://doi.org/10.1016/j.mucimm.2025.10.007.

Sampsonas, F. et al. (2026) ‘Post-stroke sleep disordered breathing and the effect of positive airway pressure treatment: An updated systematic review and meta-analysis of randomized control trials’, 85. Available at: https://doi.org/10.1016/j.smrv.2025.102207.

Chen, Mao (2026) Genetic deletion of the inflammatory bowel disease-associated risk gene Rgs14 aggravates experimental colitis. Doctoral Thesis. University of Basel.

Niess, Jan Hendrik, Kimberley Heinsalo, Ashley and Melhem, Hassan (2026) ‘Potential approaches in repairing the damaged epithelial barrier in eosinophilic esophagitis’, Expert Review of Clinical Immunology, 22, pp. 145–154. Available at: https://doi.org/10.1080/1744666x.2026.2641531.

Niess, Jan Hendrik and Kaymak, Tanay (2025) ‘Eosinophilic Esophagitis Pathogenesis: All Clear?’, Inflamm Intest Dis. 08.05.2025, 10(1), pp. 135–150. Available at: https://doi.org/10.1159/000546241.

Schmitt, Andreas M et al. (2025) ‘Nebenwirkungen von Immuncheckpoint-Inhibitoren in der Gastroenterologie’, Schweizer Gastroenterologie. 07.11.2025, 6, pp. 124–131. Available at: https://doi.org/10.1007/s43472-025-00182-9.

Niess, Jan Hendrik and von Strauss und Torney, Marco (2025) ‘Crohn-Update: Operation oder Medikamente?’, Schweizer Gastroenterologie, 6(4), pp. 118–123. Available at: https://doi.org/10.1007/s43472-025-00181-w.

Casas Deza, D. et al. (2025) ‘Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg)’, 120(11), pp. 2644–2659. Available at: https://doi.org/10.14309/ajg.0000000000003351.

Doulberis, M. et al. (2025) ‘Unraveling the pathogenetic overlap of Helicobacter pylori and metabolic syndrome-related Porphyromonas gingivalis: Gingipains at the crossroads and as common denominator’, 299. Available at: https://doi.org/10.1016/j.micres.2025.128255.

Eleftheriou, M. et al. (2025) ‘Risk factors as criteria for drain use in gastrectomy: A prospective study’, 23(2). Available at: https://doi.org/10.3892/mco.2025.2870.

Doulberis, M. and Kremer, A.E. (2025) ‘CD19 als Gamechanger bei IgG 4‑assoziierter Erkrankung: Erwartungen an Inebilizumab und Ergebnisse der ersten randomisierten kontrollierten Studie’, Schweizer Gastroenterologie, 6(2), pp. 78–80. Available at: https://doi.org/10.1007/s43472-025-00170-z.

Li, Hainan et al. (2025) ‘G Protein–Coupled Receptor 35 Suppresses Oxidative Stress Responsive Kinase 1 in Diabetic Wound Healing’, Diabetes, 74(7), pp. 1233–1246. Available at: https://doi.org/10.2337/db24-0737.

Ebrahimi, Ramin et al. (2025) ‘Increased Risk of Cardiovascular Events After Coronary Interventions in Inflammatory Bowel Disease: A Nationwide Matched Cohort Study’, Alimentary Pharmacology and Therapeutics, 61, pp. 1904–1912. Available at: https://doi.org/10.1111/apt.70162.

Rubin, D.T. et al. (2025) ‘Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis’, Inflammatory Bowel Diseases, 31(6), pp. 1630–1636. Available at: https://doi.org/10.1093/ibd/izae204.

Jallouli, I., Doulberis, M. and Kountouras, J. (2025) ‘Primary biliary cholangitis: a summary of pathogenesis and therapies’, 38(2), pp. 121–132. Available at: https://doi.org/10.20524/aog.2025.0953.

Mona, Robin et al. (2025) ‘Fatigue Is Strongly Associated with Depressive Symptoms in Patients with Inflammatory Bowel Disease’, Inflammatory Intestinal Diseases, 10, pp. 90–103. Available at: https://doi.org/10.1159/000545572.

Kountouras, J. et al. (2025) ‘Potential impact of Helicobacter pylori infection on primary-angle closure glaucoma and primary open-angle glaucoma pathophysiology’, 567, pp. 271–272. Available at: https://doi.org/10.1016/j.neuroscience.2025.01.002.

Dylgjeri, Sara (2025) Cytochrome-dependent mucosal immune responses. Doctoral Thesis. University of Basel.

Loutroukis, T. et al. (2025) ‘Studying the Prevalence and Causes of Maxillofacial Dental Infections in Patients Referred to the Maxillofacial Surgery Department’, Turkish journal of Dental Hygiene, 5(1), pp. 1–8. Available at: https://doi.org/10.51847/nchzrjquvm.

Marinucci, Mattia (2025) Molecular and metabolic dynamics in cancer: therapeutic insights for metastatic colorectal cancer and hepatocellular carcinoma. Doctoral Thesis. University of Basel.

Milivojevic, V. et al. (2025) ‘The implementation of PCR-guided therapy in the eradication of Helicobacter pylori: experience from the European Registry on H. pylori management (Hp-EuReg)’, Revista Española de Enfermedades Digestivas [Preprint]. Available at: https://doi.org/10.17235/reed.2025.11699/2025.

Morsy, Yasser et al. (2025) ‘Blood-borne immune cells carry low biomass DNA remnants of microbes in patients with colorectal cancer or inflammatory bowel disease’, Gut Microbes, 17. Available at: https://doi.org/10.1080/19490976.2025.2530157.

Olmedo, L. et al. (2025) ‘Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg)’, 74(1), pp. 15–25. Available at: https://doi.org/10.1136/gutjnl-2024-332804.

Woelfel, Simon et al. (2025) ‘XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease’, Alimentary Pharmacology and Therapeutics, 61, pp. 299–312. Available at: https://doi.org/10.1111/apt.18349.

Lehmann, Anouk et al. (2024) ‘Risankizumab and Certolizumab Pegol Dual-Targeted Therapy for Crohn’s Disease and Axial Spondyloarthritis: A Case Report’, Case Reports in Gastroenterology, 19, pp. 22–30. Available at: https://doi.org/10.1159/000542759.

Biedermann, Luc et al. (2024) ‘Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial’, Nutrients, 16(23). Available at: https://doi.org/10.3390/nu16234197.

Salahi-Niri, A. et al. (2024) ‘Global prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis’, 22(1). Available at: https://doi.org/10.1186/s12916-024-03816-y.

Woelfel, Simon et al. (2024) ‘STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease’, Vaccines, 12(11). Available at: https://doi.org/10.3390/vaccines12111241.

Zimmerli, M. et al. (2024) ‘Over -the –scope (OTSC) clips for high –risk nonvaricealupper GI bleeding – real world data on usability and efficacy’, Swiss Medical Weekly . 09.09.2024. SMW supporting association, 154(Supplementum 281).

Byndloss, Mariana et al. (2024) ‘The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications—2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum’, Diabetes Care, 73(9), pp. 1391–1410. Available at: https://doi.org/10.2337/dbi24-0028.

Byndloss, Mariana et al. (2024) ‘The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications—2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum’, Diabetes Care, 47(9), pp. 1491–1508. Available at: https://doi.org/10.2337/dci24-0052.

Byndloss, Mariana et al. (2024) ‘The gut microbiota and diabetes: research, translation, and clinical applications – 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum’, Diabetologia. 24.06.2024, 67(9), pp. 1760–1782. Available at: https://doi.org/10.1007/s00125-024-06198-1.

Kountouras, J. et al. (2024) ‘Letter: Role of Helicobacter pylori and metabolic syndrome-related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH’, 60(5), pp. 660–661. Available at: https://doi.org/10.1111/apt.18124.

Melhem, H. and Niess, J.H. (2024) ‘Eosinophilic Esophagitis and Inflammatory Bowel Disease: What Are the Differences?’, International Journal of Molecular Sciences, 25(15), p. 8534. Available at: https://doi.org/10.3390/ijms25158534.

Wakim El-Khoury, Jeanine et al. (2024) ‘Cohort Profile Update: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS)’, Inflammatory Intestinal Diseases. 17.07.2024, 9(1), pp. 165–173. Available at: https://doi.org/10.1159/000539713.

Yumusak, O. and Doulberis, M. (2024) ‘Update on cirrhotic cardiomyopathy: from etiopathogenesis to treatment’, 37(4), pp. 381–391. Available at: https://doi.org/10.20524/aog.2024.0885.

Huguet, J.M. et al. (2024) ‘Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management’, 12(6), pp. 691–704. Available at: https://doi.org/10.1002/ueg2.12569.

Woelfel, S. et al. (2024) ‘Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease’, Vaccines, 12(7), p. 774. Available at: https://doi.org/10.3390/vaccines12070774.

Kaymak, Tanay and Niess, Jan Hendrik (2024) ‘Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis’, Journal of Visualized Experiments , 2024(207). Available at: https://doi.org/10.3791/66503.

Kountouras, J. et al. (2024) ‘Impact of Helicobacter pylori and metabolic syndrome on mast cell activation-related pathophysiology and neurodegeneration’, 175. Available at: https://doi.org/10.1016/j.neuint.2024.105724.

Kountouras, J. et al. (2024) ‘EP100 THE MULTIDIMENSIONAL/ANTIBACTERIAL BENEFIT OF TRIMEBUTINE MALEATE ON FUNCTIONAL DYSPEPSIA: A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND CONTROLLED STUDY’, Gastroenterology, 166(5), pp. S–1528. Available at: https://doi.org/10.1016/s0016-5085(24)03958-1.

Kountouras, J. et al. (2024) ‘Comment on: Association between Helicobacter pylori infection and incident risk of dementia: The AMI cohort’, 72(5), pp. 1557–1559. Available at: https://doi.org/10.1111/jgs.18929.

Bettschen, D. et al. (2024) ‘Epidemiology of maxillofacial trauma in elderly patients receiving oral anticoagulant or antithrombotic medication; a Swiss retrospective study’. Springer Science and Business Media LLC. Available at: https://doi.org/10.21203/rs.3.rs-4014065/v1.

Baldrich, Adrian et al. (2024) ‘Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency’, Journal of Clinical Immunology, 44(3). Available at: https://doi.org/10.1007/s10875-024-01667-z.

Maria Tzitiridou-Chatzopoulou et al. (2024) ‘A potential impact of the immunological profile of current covid-19 vaccines on pregnancy outcomes’, World Journal of Advanced Research and Reviews, 21(2), pp. 270–275. Available at: https://doi.org/10.30574/wjarr.2024.21.2.0414.

Devan, Jan et al. (2024) ‘Surface protein and functional analyses identify CD4+CD39+ TCR αβ+ and activated TCR Vδ1+ cells with distinct pro-inflammatory functions in Crohn’s disease lesions’, Clinical and experimental immunology, 215(1), pp. 79–93. Available at: https://doi.org/10.1093/cei/uxad098.

Doulberis, M. et al. (2024) ‘Impact of Helicobacter pylori and metabolic syndrome-related mast cell activation on cardiovascular diseases’, 3. Available at: https://doi.org/10.3389/fgstr.2024.1331330.

Feiden A. et al. (2024) ‘Do prophylactically placed pancreatic stents need to beremoved- a retrospective chart review’, in Swiss Medical Weekly. Interlaken: SMW supporting association (Swiss Medical Weekly), pp. 20–21.

Rybinski F. et al. (2024) ‘Green Endoscopy- potential and limitations of waste reduction strategies derived from a waste audit’, Swiss Medical Weekly . 09.09.2024. SMW supporting association, 154(Supplementum 281).

Lautenschlager S.A. et al. (2023) ‘Lifestyle factors associated with inflammatory bowel disease: data from the Swiss IBD cohort study’, BMC Gastroenterology, 23(1). Available at: https://doi.org/10.1186/s12876-023-02692-9.

Miyamoto K et al. (2023) ‘The gut microbiota-induced kynurenic acid recruits GPR35-positive macrophages to promote experimental encephalitis’, Cell Reports, 42(8), p. 113005. Available at: https://doi.org/10.1016/j.celrep.2023.113005.

Kaymak, Tanay et al. (2023) ‘IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis’, Gut, 72(5), pp. 821–833. Available at: https://doi.org/10.1136/gutjnl-2022-327166.

Casas, D. et al. (2023) ‘127 - IMPACTO DEL USO DE PROBIÓTICOS EN LA SEGURIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)’, Gastroenterología y Hepatología, 46, p. S159. Available at: https://doi.org/10.1016/s0210-5705(23)00259-5.

Jonaitis, P. et al. (2023) ‘130 - COMPARACIÓN DE LA EFECTIVIDAD DE LOS TRATAMIENTOS ERRADICADORES MÁS FRECUENTES ENTRE LAS POBLACIONES MÁS MAYORES Y MÁS JÓVENES DE EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)’, Gastroenterología y Hepatología, 46, p. S162. Available at: https://doi.org/10.1016/s0210-5705(23)00262-5.

Nyssen, O.P. et al. (2023) ‘135 - TENDENCIAS DE PRESCRIPCIÓN DE TRATAMIENTOS ERRADICADORES Y DE SU EFECTIVIDAD EN PACIENTES NAÏVE A LO LARGO DE 10 AÑOS (2013-2022) EN EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)’, Gastroenterología y Hepatología, 46, p. S167. Available at: https://doi.org/10.1016/s0210-5705(23)00267-4.

Pop, Oltin-Tiberiu et al. (2023) ‘AXL Expression on Homeostatic Resident Liver Macrophages Is Reduced in Cirrhosis Following GAS6 Production by Hepatic Stellate Cells’, Cellular and Molecular Gastroenterology and Hepatology, 16(1), pp. 17–37. Available at: https://doi.org/10.1016/j.jcmgh.2023.03.007.

Sulz, Michael Christian et al. (2023) ‘Childlessness in Patients with Inflammatory Bowel Disease – Data from the Prospective Multi-center Swiss IBD Cohort Study’, Journal of Gastrointestinal and Liver Diseases, 32(4), pp. 460–468. Available at: https://doi.org/10.15403/jgld-5132.

Serra, Eva Gonçalves et al. (2022) ‘Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease (Nature Communications, (2020), 11, 1, (995), 10.1038/s41467-019-14275-y)’, Nature Communications , 13(1). Available at: https://doi.org/10.1038/s41467-022-31010-2.

Jordi, Sebastian Bruno Ulrich et al. (2022) ‘The personality traits activity, self-reproach, and negative affect jointly predict clinical recurrence, depressive symptoms, and low quality of life in inflammatory bowel disease patients’, Journal of Gastroenterology, 57(11), pp. 848–866. Available at: https://doi.org/10.1007/s00535-022-01902-7.

Kountouras, J. et al. (2022) ‘Potential impact of Helicobacter pylori and metabolic syndrome-related non-alcoholic fatty liver disease on cardio-cerebrovascular disease’, 135. Available at: https://doi.org/10.1016/j.metabol.2022.155276.

Casadó-Llombart S et al. (2022) ‘Experimental and genetic evidence for the impact of CD5 and CD6 expression and variation in inflammatory bowel disease’, Frontiers in Immunology, 13, p. 966184. Available at: https://doi.org/10.3389/fimmu.2022.966184.

Kaymak T, Hruz P and Niess JH (2022) ‘Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases’, FEBS Journal, 289(16), pp. 4758–4772. Available at: https://doi.org/10.1111/febs.16103.

Mukaddam K et al. (2022) ‘Cytokines Activate JAK–STAT Signaling Pathway in MG-63 Cells on Titanium and Zirconia’, Materials, 15(16). Available at: https://doi.org/10.3390/ma15165621.

Müller A et al. (2022) ‘[The IBD-Control questionnaire: German translation and validation of the standardized questionnaire for Patient Reported Outcome Measurement in inflammatory bowel disease].’, Zeitschrift fur Gastroenterologie, 60(6), pp. 911–926. Available at: https://doi.org/10.1055/a-1482-8642.

Noubissi Nzeteu GA et al. (2022) ‘Macrophage Differentiation and Polarization Regulate the Release of the Immune Checkpoint Protein V-Domain Ig Suppressor of T Cell Activation’, Frontiers in Immunology, 13, p. 837097. Available at: https://doi.org/10.3389/fimmu.2022.837097.

Jordi, Sebastian Bruno Ulrich et al. (2022) ‘Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease’, Inflammatory Bowel Diseases, 28(4), pp. 560–571. Available at: https://doi.org/10.1093/ibd/izab136.

Melhem, Hassan et al. (2022) ‘Epithelial GPR35 protects from Citrobacter rodentium infection by preserving goblet cells and mucosal barrier integrity’, Mucosal Immunology, 15(3), pp. 443–458. Available at: https://doi.org/10.1038/s41385-022-00494-y.

Walldorf J et al. (2022) ‘The Selective 5-HT1A Agonist SR57746A Protects Intestinal Epithelial Cells and Enteric Glia Cells and Promotes Mucosal Recovery in Experimental Colitis’, Inflammatory Bowel Diseases, 28(3), pp. 423–433. Available at: https://doi.org/10.1093/ibd/izab191.

Schlichtner S et al. (2022) ‘Expression of the Immune Checkpoint Protein VISTA Is Differentially Regulated by the TGF-β1 – Smad3 Signaling Pathway in Rapidly Proliferating Human Cells and T Lymphocytes’, Frontiers in Medicine, 9, p. 790995. Available at: https://doi.org/10.3389/fmed.2022.790995.

Lett, Martin J et al. (2022) ‘Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells’, Gut, 71(12), pp. 2526–2538. Available at: https://doi.org/10.1136/gutjnl-2021-324478.

Lett, Martin J et al. (2022) ‘Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells’, Gut, 71(12), pp. 2526–2538. Available at: https://doi.org/10.1136/gutjnl-2021-324478.

Mukaddam, Khaled et al. (2022) ‘Novel Titanium Nanospike Structure Using Low-Energy Helium Ion Bombardment for the Transgingival Part of a Dental Implant’, Nanomaterials, 12(7), p. 1065. Available at: https://doi.org/10.3390/nano12071065.

Ledergerber, Martina et al. (2021) ‘Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management’, BMC Gastroenterology, 21(1). Available at: https://doi.org/10.1186/s12876-021-01622-x.

Melhem H, Regan-Komito D and Niess JH (2021) ‘Mucins dynamics in physiological and pathological conditions’, International Journal of Molecular Sciences, 22(24). Available at: https://doi.org/10.3390/ijms222413642.

Yoganathan, Priyatharsan et al. (2021) ‘Genotype–phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients’, BMC Gastroenterology, 21(1). Available at: https://doi.org/10.1186/s12876-021-01880-9.

Yoganathan P. et al. (2021) ‘Genotype–phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients’, BMC Gastroenterology, 21(1). Available at: https://doi.org/10.1186/s12876-021-01880-9.

Kaya B, Melhem H and Niess JH (2021) ‘GPR35 in Intestinal Diseases: From Risk Gene to Function’, Frontiers in Immunology, 12, p. 717392. Available at: https://doi.org/10.3389/fimmu.2021.717392.

Schlichtner S et al. (2021) ‘Functional role of galectin-9 in directing human innate immune reactions to Gram-negative bacteria and T cell apoptosis’, International Immunopharmacology, 100, p. 108155. Available at: https://doi.org/10.1016/j.intimp.2021.108155.

Sutter M, Hruz P and Niess JH (2021) ‘High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients’, Inflammatory Intestinal Diseases, 6(3), pp. 165–174. Available at: https://doi.org/10.1159/000518264.

Jordi S.B.U. et al. (2021) ‘Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease’, Alimentary Pharmacology and Therapeutics, 54(1), pp. 53–67. Available at: https://doi.org/10.1111/apt.16365.

Teo Hansen Selnø A et al. (2021) ‘High Mobility Group Box 1 (HMGB1) Induces Toll-Like Receptor 4-Mediated Production of the Immunosuppressive Protein Galectin-9 in Human Cancer Cells’, Frontiers in Immunology, 12, p. 675731. Available at: https://doi.org/10.3389/fimmu.2021.675731.

Doulberis, M. et al. (2021) ‘Gastrointestinal and hepatobiliary disorders of patients from countries with low to middle income: a retrospective observational study in a Swiss emergency department’, Archives of Medical Science – Civilization Diseases, 6(1), pp. 36–45. Available at: https://doi.org/10.5114/amscd.2021.105524.

Mukaddam, Khaled et al. (2021) ‘Effect of a Nanostructured Titanium Surface on Gingival Cell Adhesion, Viability and Properties against P. gingivalis’, Materials, 14(24), p. 7686. Available at: https://doi.org/10.3390/ma14247686.

Schreiner P. et al. (2021) ‘Fatigue in inflammatory bowel disease and its impact on daily activities’, Alimentary Pharmacology and Therapeutics, 53(1), pp. 138–149. Available at: https://doi.org/10.1111/apt.16145.

Herrema H and Niess JH (2020) ‘Intestinal microbial metabolites in human metabolism and type 2 diabetes’, Diabetologia, 63(12), pp. 2533–2547. Available at: https://doi.org/10.1007/s00125-020-05268-4.

Selnø ATH et al. (2020) ‘Transforming growth factor beta type 1 (TGF-β) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells’, Aging, 12(23), pp. 23478–23496. Available at: https://doi.org/10.18632/aging.202343.

Serra E.G. et al. (2020) ‘Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease’, Nature Communications, 11(1). Available at: https://doi.org/10.1038/s41467-019-14275-y.

Wuggenig, Philipp et al. (2020) ‘Loss of the branched-chain amino acid transporter CD98hc alters the development of colonic macrophages in mice’, Communications Biology, 3(1). Available at: https://doi.org/10.1038/s42003-020-0842-3.